// App-Quantinova.ai

THU0188 : EFFICACY OF FILGOTINIB IN PATIENTS WITH RHEUMATOID ARTHRITIS WITH POOR PROGNOSTIC FACTORS: POST HOC ANALYSIS OF FINCH 3

Researchers

Presenter

  • D. Aletaha

Principal Investigators

  • R. Westhovens

  • C. Gaujoux-Viala

  • G. Adami

  • A. Matsumoto

  • P. Bird

  • O. Messina

  • M. H. Buch

  • B. Bartok

  • Z. Yin

  • Y. Guo

  • T. Hendrikx

  • G. R. Burmester

Medical Centers

  • Medical University of Vienna, Vienna, Austria

  • Univ Hosps Leuven, Leuven, Belgium

  • Univ de Montpellier, Nîmes, France

  • University of Verona, Verona, Italy

  • Arthritis and Rheumatism Assoc, Wheaton, MD, United States of America

  • Univ of New South Wales, Sydney, Sydney, Australia

  • IRO Medical Ctr, Buenos Aires, Argentina

  • Cosme Argerich Hospital, Buenos Aires, Argentina

  • University of Manchester, Manchester, United Kingdom

  • Gilead Sciences, Inc., Foster City, CA, United States.

  • Galapagos, Nv, Leiden, The Netherlands

  • Charite Univsmedizin Berlin, Berlin, Germany

Locations

  • Austria

  • Belgium

  • France

  • Italy

  • United States

  • Australia

  • Argentina

  • United Kingdom

  • Netherlands

  • Germany

Companies

  • N/A

Study Components

Therapeutic Area

  • Autoimmune (AI)

Disease

  • Rheumatoid arthritis

Biomarkers

  • anti-CCP antibodies

  • C reactive protein

  • High sensitivity C-reactive protein

Drug/Treatment

  • Filgotinib

Outcome

  • N/A

Study Design

  • Randomized

  • Double Blind/Blinded

  • Controlled

Phase

  • III

Study Id's

  • NCT02886728

Sponsors

  • Abbvie

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved